Triazole DAGLα inhibitors

US10583137B2 · kind B2 · utility

Assignees

• THE SCRIPPS RESEARCH INSTITUTE · US
• Leiden University · NL

Inventors

• Benjamin F. Cravatt · San Diego, US
• Daisuke OGASAWARA · Machida, JP
• Andreu Viader · San Diego, US
• Hui DENG · Leiden, NL
• Tom Van Der Wel · Voorburg, NL
• Marcelis van der Stelt · Oss, NL

Key dates

• Filing date: Dec 2, 2016
• Grant date: Mar 10, 2020
• Expiry date: Dec 2, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are triazole compounds and pharmaceutical compositions comprising said compounds useful as modulators of DAGL(α) and DAGL(β). In some embodiments, the compounds described herein are selective DAGL(α) inhibitors. Furthermore, the subject compounds and compositions are useful for the treatment of neurodegenerative or neuroinflammatory disease.